Physician profile
Douglas Mcfadden
NPI 1689601981
$2,079.73
in general payments reported to CMS, 2019-2025
14 companies · $924 in 2025
The $924 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11.37 · 2022: $367 · 2023: $313 · 2024: $465 · 2025: $924.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,687 · Education: $13.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,687.37 |
| Education | $13.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $688.37 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $325.33 | 2021-2025 | Otezla, Repatha, Evenity |
| Astrazeneca Pharmaceuticals LP | $285.12 | 2024-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $269.63 | 2022-2025 | Mounjaro, Zepbound, Kisunla |
| Pfizer INC. | $149.49 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $146.00 | 2025 | |
| Abbott Laboratories | $64.14 | 2024-2025 | Freestyle Libre 3 |
| Exact Sciences Corporation | $41.76 | 2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $31.44 | 2023 | Trelegy Ellipta |
| Sanofi-Aventis U.S. LLC | $20.50 | 2022 | |
| Esperion Therapeutics, INC. | $18.18 | 2022 | |
| Boston Scientific Corporation | $17.87 | 2025 | Watchman Access System |
| Sumitomo Pharma America, INC. | $14.40 | 2025 | Gemtesa |
| Penumbra, INC. | $7.50 | 2023 | Indigo System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Mcfadden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.